Tania Fleitas

4.2k total citations · 1 hit paper
58 papers, 2.3k citations indexed

About

Tania Fleitas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Tania Fleitas has authored 58 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Tania Fleitas's work include Gastric Cancer Management and Outcomes (19 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Genomics and Diagnostics (10 papers). Tania Fleitas is often cited by papers focused on Gastric Cancer Management and Outcomes (19 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Genomics and Diagnostics (10 papers). Tania Fleitas collaborates with scholars based in Spain, United Kingdom and Italy. Tania Fleitas's co-authors include Andrés Cervantes, Elizabeth Smyth, Valentina Gambardella, Guillaume Piessen, Arndt Vogel, Fátima Carneiro, Karin Haustermans, Stefano Cascinu, Florian Lordick and Susana Roselló and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Tania Fleitas

53 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 646 citations Florian Lordick, Tania Fleitas et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Tania Fleitas

Since Specialization

Citations

This map shows the geographic impact of Tania Fleitas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tania Fleitas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tania Fleitas more than expected).

Fields of papers citing papers by Tania Fleitas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tania Fleitas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tania Fleitas. The network helps show where Tania Fleitas may publish in the future.

Co-authorship network of co-authors of Tania Fleitas

This figure shows the co-authorship network connecting the top 25 collaborators of Tania Fleitas. A scholar is included among the top collaborators of Tania Fleitas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tania Fleitas. Tania Fleitas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Smart CAR-T Nanosymbionts: archetypes and proto-models 2025 ·Frontiers in Immunology ·(unknown), Jorge Victoria, (unknown), (unknown), Joshua Ortiz‐Guzman, Juan Esteban García-Robledo, (unknown), (unknown), Ludwig L. Albornóz, (unknown), Carlos A. Cañas, Gustavo Cruz, (unknown), Tania Fleitas, Ivan Laponogov, Alexandrе Loukanov, Kirill Veselkov	3
2	Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life 2025 ·Cancer Treatment Reviews ·(unknown), Susana Roselló, Noelia Tarazona, Marisol Huerta, (unknown), Tania Fleitas, Vicente Pla‐Martí, Alberto Puccini, Desamparados Roda, Andrés Cervantes	0
3	Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids 2025 ·Journal of Experimental & Clinical Cancer Research ·Federica Papaccio, Manuel Cabeza-Segura, (unknown), Francisco Gimeno-Valiente, S. Zúñiga, Valentina Gambardella, (unknown), Carolina Martínez‐Ciarpaglini, (unknown), Tania Fleitas, (unknown), Juan Antonio Carbonell‐Asins, Marisol Huerta, David Moro‐Valdezate, Desamparados Roda, Noelia Tarazona, Manuel M. Sánchez del Pino, Andrés Cervantes, Josefa Castillo	4
4	Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma 2024 ·Med ·María Alsina, Tania Fleitas	0
5	O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study 2023 ·Annals of Oncology ·Elizabeth Smyth, M. Mauer, Chiara Alessandra Cella, Irit Ben‐Aharon, Guillaume Piessen, Lucjan Wyrwicz, (unknown), Tania Fleitas, Valérie Boige, M. Stahl, Uwe M. Martens, Radka Obermannová, Carlos Gómez-Martín, Peter Thuss‐Patience, Virginia Arrazubi, Antonio Avallone, Kai‐Keen Shiu, (unknown), (unknown), Florian Lordick	9
6	“Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction” 2023 ·Journal of Experimental & Clinical Cancer Research ·Federica Papaccio, (unknown), Francisco Gimeno-Valiente, Manuel Cabeza-Segura, Valentina Gambardella, (unknown), Clara Alfaro‐Cervelló, Carolina Martínez‐Ciarpaglini, Pilar Rentero-Garrido, S. Zúñiga, Juan Antonio Carbonell‐Asins, Tania Fleitas, Susana Roselló, Marisol Huerta, Manuel M. Sánchez del Pino, Luís Sabater, Desamparados Roda, Noelia Tarazona, Andrés Cervantes, Josefa Castillo	49
7	P-53 A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma 2022 ·Annals of Oncology ·Geoffrey Y. Ku, Sarina A. Piha‐Paul, (unknown), Dong Yoon Oh, (unknown), (unknown), Sun Young Rha, Yujin Kang, M. Díez García, Tania Fleitas, Virginia Arrazubi, (unknown), (unknown)	4
8	In the literature: October 2021 2021 ·ESMO Open ·Valentina Gambardella, Carolina Martínez‐Ciarpaglini, Tania Fleitas, Andrés Cervantes	1
9	488P Patient-derived organoids as a tool for modelling localized colorectal cancer 2020 ·Annals of Oncology ·Miren Bravo, Federica Papaccio, (unknown), Carolina Martínez‐Ciarpaglini, Clara Alfaro‐Cervelló, (unknown), (unknown), (unknown), Valentina Gambardella, Pilar Rentero-Garrido, Tania Fleitas, David Moro‐Valdezate, Marisol Huerta, Noelia Tarazona, D. Roda, Andrés Cervantes, Josefa Castillo	2
10	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target 2020 ·Cancer Treatment Reviews ·Valentina Gambardella, Josefa Castillo, Noelia Tarazona, Francisco Gimeno-Valiente, Carolina Martínez‐Ciarpaglini, Manuel Cabeza-Segura, Susana Roselló, D. Roda, Marisol Huerta, Andrés Cervantes, Tania Fleitas	232
11	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma 2019 ·Annals of Oncology ·Valentina Gambardella, Tania Fleitas, Noelia Tarazona, Juan Miguel Cejalvo, Francisco Gimeno-Valiente, Carolina Martínez‐Ciarpaglini, Marisol Huerta, Susana Roselló, Josefa Castillo, D. Roda, Andrés Cervantes	20
12	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer 2019 ·ESMO Open ·Juan Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas, Enriqueta Felip, Alejandro Navarro, Maria Martinez‐García, (unknown), Natasha B. Leighl, Ulrik Lassen, Morten Mau‐Sørensen, Céline Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Maja Weisser, Andrés Cervantes	22
13	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer 2019 ·Annals of Oncology ·N. Tarazona, Francisco Gimeno-Valiente, Valentina Gambardella, S. Zúñiga, Pilar Rentero-Garrido, Marisol Huerta, Susana Roselló, Carolina Martínez‐Ciarpaglini, Juan Antonio Carbonell‐Asins, (unknown), (unknown), G. Bruixola, Tania Fleitas, (unknown), (unknown), D Moro, Josefa Castillo, Alejandro Espí, Desamparados Roda, Andrés Cervantes	190
14	In the literature: June 2019 2019 ·ESMO Open ·Ángela Lamarca, Valentina Gambardella, Juan Miguel Cejalvo, Tania Fleitas, Andrés Cervantes	3
15	Gene expression changes responsible for lapatinib acquired resistance in HER2 positive gastric cancer cell lines: a microarray analysis 2017 ·Annals of Oncology ·Valentina Gambardella, Josefa Castillo, Francisco Gimeno-Valiente, Noelia Tarazona, Marisol Huerta, Desamparados Roda, Tania Fleitas, Gloría Ribas, Susana Roselló, Eva Serna, Andrés Cervantes	1
16	A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer 2016 ·Annals of Oncology ·Juan Miguel Cejalvo, Tania Fleitas, Enriqueta Felip, Alejandro Navarro, Maria Martinez‐García, Álvaro Taus, Natasha B. Leighl, Ulrik Lassen, (unknown), Céline Adessi, Francesca Michielin, Wolfgang Jacob, Ian James, Maurizio Ceppi, Maja Weisser, Andrés Cervantes	3
17	Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma 2015 ·Anti-Cancer Drugs ·Gaspar Reynés, Vicenta Martı́nez-Sales, Virtudes Vila, Carmen Balañá, Pedro Pérez‐Segura, María Ángeles Vaz Salgado, Manuel Benavides, Óscar Gallego, (unknown), Miguel Gil‐Gil, Tania Fleitas, (unknown)	12
18	VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer 2013 ·Clinical & Translational Oncology ·Tania Fleitas, Vicenta Martı́nez-Sales, V. Vila, E. Regañón, (unknown), (unknown), José Gómez‐Codina, Joaquín Montalar, Gaspar Reynés	28
19	Circulating Endothelial Cells and Microparticles as Prognostic Markers in Advanced Non-Small Cell Lung Cancer 2012 ·PLoS ONE ·Tania Fleitas, Vicenta Martı́nez-Sales, Virtudes Vila, Edelmiro Regañón, (unknown), (unknown), José Gómez‐Codina, Joaquín Montalar, Gaspar Reynés	63
20	Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables 2007 ·Clinical & Translational Oncology ·José Ponce, (unknown), Robert Díaz Beveridge, (unknown), Francisco Aparisi, Tania Fleitas, (unknown), (unknown), (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact